<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/0267A689-CC26-4FC4-B1C6-775067CB0949"><gtr:id>0267A689-CC26-4FC4-B1C6-775067CB0949</gtr:id><gtr:name>Oval Medical Technologies Limited</gtr:name><gtr:address><gtr:line1>THE INNOVATION CENTRE UNIT 23 , CAMBRIDGE SCIENCE PARK</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0267A689-CC26-4FC4-B1C6-775067CB0949" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>0267A689-CC26-4FC4-B1C6-775067CB0949</gtr:id><gtr:name>Oval Medical Technologies Limited</gtr:name><gtr:address><gtr:line1>THE INNOVATION CENTRE UNIT 23 , CAMBRIDGE SCIENCE PARK</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>228256.0</gtr:offerGrant><gtr:projectCost>507236.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720430"><gtr:id>1284FD81-2AF6-4407-AE10-6D0D2A68A275</gtr:id><gtr:title>Oval Medical - Primary Drug Container Foil Feed, Seal and Finish Process for Aseptic Enviroment.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720430</gtr:grantReference><gtr:abstractText>Oval Medical Technologies Ltd design, develop and aim to manufacture auto injectors to
support patients self administer injection of drug for various therapy treatments. Multiple
drugs are already available to patients for the treatment of various conditions such as
Rheumatoid arthritis, Multiple Sclerosis, and Cancer,
Auto Injectors have been available since the 1980?s, predominantly as reusable devices and
since 2006 more single use disposable applications have emerged. However, today?s
technology of auto injectors is based around the standard 1ml glass syringe which was
developed in the 1950?s and certainly not developed for use in auto injectors. This leads to
unreliability of function, provides limitation for drug stability and constrains auto injector
design for ease of use and compliance by the patient.
Oval Medical has developed a novel drug container specifically designed for use in an auto
injector with optimal performance for Patient use, reliability and improved drug stability. The
novel container has been design in plastic, allowing the moulding of specific shapes and form
to optimise the auto injector design and all drug contact materials are manufactured from inert
plastics allowing optimal drug stability.
Oval has shown in 4 user studies that devices based on this novel patented technology are
better for patients with significantly fewer use errors than marketed devices and are preferred
by patients.
The novel drug container closure system consists of a polyethylene cup seal and welded
aluminium foil. Whilst the process of foiling plastic containers is widely used, it is novel in an
aseptic parenteral drug filling environment. This project seeks to resolve mechanical and
environmental condition and control issues to bring a commercially viable process to market
through the realisation of a prototype foiling process capable of installation in an aseptic
environment</gtr:abstractText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>228256</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720430</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>